A New Paradigm in Drug Development - The mission of Bio-Path is to make its neutral lipid delivery the standard delivery technology for antisense therapeutics in the pharmaceutical industry.
Liposomal Grb-2 Clinical Trial

Bio-Path completed six cohorts of the Phase I clinical trial evaluating Liposomal Grb-2 in blood cancers. The drug’s safety profile continues to be favorable with no treatment-related serious adverse events reported and data suggests possible anti-leukemia activity. A maximum tolerated dose has yet to be reached. The clinical trial is being conducted at the MD Anderson Cancer Center.

Patients are currently being enrolled into a safety segment of a Phase II program evaluating Liposomal Grb-2 in combination with Ara-C for AML.

Latest News

May 12, 2015
Bio-Path Holdings Reports First Quarter 2015 Operational and Financial Results

May 6, 2015
Slides from Presentation at IBC's 17th Annual TIDES Oligonucleotide and Peptide Therapeutics Conference

Apr 28, 2015
Bio-Path Holdings Granted Orphan Drug Designation for Liposomal Grb-2 in Acute Myeloid Leukemia

Apr 24, 2015
Letter to Shareholders from President and CEO

Apr 22, 2015
Bio-Path Holdings' Drug Delivery Technology to be Featured in a Presentation at IBC's 17th Annual TIDES Oligonucleotide and Peptide Therapeutics Conference

Mar 17, 2015
Bio-Path Holdings Reports Fiscal Year 2014 Operational and Financial Results

Mar 5, 2015
Letter to Shareholders from President and CEO

Feb 9, 2015
Bio-Path Holdings Starts Phase II Study with Liposomal Grb-2 in AML Patients